A comprehensive assessment of the physical and biological effects of patients with prostate cancer in hong kong
NCT ID NCT03344835
First seen Oct 22, 2026 · Last updated Oct 23, 2026 · Updated 1 time
Summary
Prostate cancer (PCa) is ranked 3rd in annual incidence of male cancer and ranked 5th for cancer-related death in men in Hong Kong which accounts for about 9.1 deaths per 100,000 men in 2011. Its incidence is rising rapidly, almost tripled in the past 10 years. In Hong Kong, the two main screening methods for PCa are digital rectal examination (DRE) and serum prostate-specific antigen (PSA) level blood test, and the gold standard of diagnosis of PCa is transrectal ultrasound (TRUS) with prostate biopsy. For those who diagnosed with PCa, there are different kinds of managements depending on patient's age group and disease stage. Watchful waiting is for older patients who presents with low-risk prostate cancer. And active surveillance is applicable to patients who are eligible for potentially curative management. While radiotherapy or radical prostatectomy are recommended as curative management for early stage PCa, androgen deprivation therapy (ADT) is the main treatment modality for advanced or recurrent prostate cancer. Advanced prostate cancer that recurrence is called castration refractory prostate cancer (CRPC). There are many new agents, including second line hormonal therapy, chemotherapy, androgen biosynthesis inhibitors, immunotherapy, bone targeting agents etc., available for the further management. In this study, investigators would like to establish a local prostate cancer registry to facilitate the collection of clinical information and outcomes of prostate cancer management. Hopefully, this registry can provide information regarding the epidemiology, natural history, and treatment outcomes of local prostate cancer. The information would be helpful for research, public education, health care planning and also international collaboration. Ultimately, patients and public would be benefited from these works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2016
- Expected to finish
-
Dec 2040
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients diagnosed with prostate cancer, in NDH, PWH and TMH, since 1995 would be included in the registry. Both retrospective and prospective cohort study design will be adopted in this study. Patients diagnosed with prostate cancer in the hospitals under the NTEC \& NTWC cluster will be identified in specialist clinics, wards, and during TRUS, and then enrolled to the study.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient at the age of 18 or above * Patients with clinical diagnosis of prostate cancer Exclusion Criteria: * Patients diagnosed to have ductal type of prostate cancer
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Prince of Wales Hospital
RECRUITINGShatin, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Comparison of multiparametric magnetic resonance imaging (mpMRI) versus Prostate-Specific membrane antigen positron emission tomography (PSMA-PET) for the evaluation of prostate imaging reporting and data system (PI-RADS) ≥4 lesions in the prostate transition zone: a prospective clinical study
- The investigation of new biological markers for prostate cancer diagnosis and management in chinese population
- BActinium-2: a phase 1b, 2 part, multicenter, open label study to evaluate the safety and efficacy of intravenous administration of a B7-H3 radiopharmaceutical ([225Ac]Ac AKY 2519) in participants with B7-H3 imaging positive solid tumors
- Prospective study of the effect of androgen deprivation therapy (ADT) in male patients suffered prostate cancer in asian population
- A study to evaluate patient and physician benefit/ risk preferences for treatment of metastatic prostate cancer (mPC) in hong kong: a discrete choice experiment
- A phase 1/2 clinical trial to evaluate the safety, tolerability, dosimetry, and anti-tumor activity of Ga-68-NGUL / Lu-177-DGUL in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to standard therapy